Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy

RA Kokate, P Chaudhary, X Sun, SI Thamake… - …, 2016 - Future Medicine
Nanomedicine, 2016Future Medicine
Background: Delivery of PLGA (poly [D, L-lactide-co-glycolide])-based biodegradable
nanoparticles (NPs) to antigen presenting cells, particularly dendritic cells, has potential for
cancer immunotherapy. Materials & methods: Using a PLGA NP vaccine construct CpG-NP-
Tag (CpG-ODN-coated tumor antigen [Tag] encapsulating NP) prepared using solvent
evaporation technique we tested the efficacy of ex vivo and in vivo use of this construct as a
feasible platform for immune-based therapy. Results: CpG-NP-Tag NPs were avidly …
Background
Delivery of PLGA (poly [D, L-lactide-co-glycolide])-based biodegradable nanoparticles (NPs) to antigen presenting cells, particularly dendritic cells, has potential for cancer immunotherapy.
Materials & methods
Using a PLGA NP vaccine construct CpG-NP-Tag (CpG-ODN-coated tumor antigen [Tag] encapsulating NP) prepared using solvent evaporation technique we tested the efficacy of ex vivo and in vivo use of this construct as a feasible platform for immune-based therapy.
Results
CpG-NP-Tag NPs were avidly endocytosed and localized in the endosomal compartment of bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells exposed to CpG-NP-Tag NPs exhibited an increased maturation (higher CD80/86 expression) and activation status (enhanced IL-12 secretion levels). In vivo results demonstrated attenuation of tumor growth and angiogenesis as well as induction of potent cytotoxic T-lymphocyte responses.
Conclusion
Collectively, results validate dendritic cells stimulatory response to CpG-NP-Tag NPs (ex vivo) and CpG-NP-Tag NPs’ tumor inhibitory potential (in vivo) for therapeutic applications, respectively.
Future Medicine